The study is designed to evaluate the safety, tolerability and efficacy of two doses of
pregabalin as add-on treatment in pediatric and adult subjects with Primary Generalized
Tonic-Clonic (PGTC) seizures as compared to placebo. It is hypothesized that both doses of
pregabalin will demonstrated superior efficacy when compared to placebo by reducing PGTC
seizure frequency and that pregabalin will be safe and well tolerated.